Canada markets closed

ImmunoPrecise Antibodies Ltd. (IPA.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
12.68+0.47 (+3.85%)
At close: 3:59PM EDT
Sign in to post a message.
  • T
    Terry
    IPA has attracted the attention of someone with one of the biggest followings on Twitter for small caps. He is doing an interview on Weds with IPA Mgmt. This is the Tweet that explains today's volume and price, it has a link to the interview if you're interested: https://twitter.com/JonahLupton/status/1379118185526493184?s=20
  • A
    Azfar
    Interview with the CEO is up on Youtube. If you want to know what the company does in Layman's terms, I suggest checking out the interview: https://www.youtube.com/watch?v=HDNse6En8jU
    Interview with Dr. Jennifer Bath, CEO of ImmunoPrecise ($IPA)
    www.youtube.com
  • b
    beurs
    bought more today..will be smiling later...buy when there is fear..sell when there is hype..now we are in fear time in bio stock market
  • b
    beurs
    bought more today..soon is our turn
  • K
    Kev
    why people not holding lol for long terme...lots of weak minded short term
  • b
    beurs
    Shorts start covering..
  • R
    Remon
    ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter of 2021 Fiscal Year
    Wed, March 17, 2021, 4:48 PM·7 min read

    ImmunoPrecise and Genmab enter into a technology partnership targeting infectious disease

    ImmunoPrecise and Litevax advance SARS-CoV-2 vaccine candidate for further pre-clinical evaluation

    Commenced trading on Nasdaq stock exchange

    Announced positive data from pre-clinical study of TATX-03 Polytope™ monoclonal antibody cocktail candidate against COVID-19

    IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced financial results for the third quarter of its 2021 fiscal year ended January 31, 2020.

    Q3 Fiscal 2021 Financial Highlights:

    Increased revenue for the nine months ended January 31st, 2021 by 32% to $13,035,522.

    Record adjusted EBITDA for the nine months ended January 31st, 2021 of $2,564,257, a significant increase from the $18,356 for the nine months ended January 31, 2020.

    Closed USD$21.7 million bought deal offering of common shares.

    Closed over-allotment option associated with the previously completed bought deal of USD$3.3 Million.
  • J
    Jerry
    Glad to see some excitement in the stock again.
  • b
    beurs
    Bought some more today...low volume...shorters take this down ...soon over 15 again....
  • A
    Adrian
    Thank God for a good day
  • b
    beurs
    Hope to see 15 friday..would be a good start
  • J
    JohnM
    this company is resting on the 200 day exponential moving average but that will fail and it is headed much lower. The CEO is a total poser and not enough of the promised milestones have passed.
  • M
    Max
    Why nobody talks about the deal that was closed 1 years ago between IPA and J&J for COVID vaccine?!!!! Now J&J vaccine is out and also this happened thanks to IPA researchers!!
  • D
    Don
    Not sure but wonder if all the COVID vaccines reduce need for IPA’s antibody “cocktail”. Of course they make antibodies targeted at other diseases including cancer . We need to see new positive findings from IPA.
  • G
    Gavin
    Congrats longs, IPA is ready for lift off....
  • R
    RC
    Covid treatment and prevention. That's extremely good news. I don't understand why weren't not on our way to the moon.
  • J
    JohnM
    Massive after hours dump. Something is not right here. The chart is telling us the company is about to announce some bad news.
  • j
    jerry
    Polytope Cocktail data will be released soon. Exhaustive work since April to develop multi antibody treatment almost sure to be safe and effective against new variants. Nano Medicine Consortium work in the Netherlands already half way through discovery phase since being announced Dec 30 This would be an inhaled solution able to be delivered by standard "puffers" These could be shipped anywhere to anyone with only mimimal doctor consultation before use. This company is a multiple wonder of projects and partners like Janssen (j & j) With further good fortune the next step may be a massive partner to truly take this global in scale. The current valuation only accounts for the revenues Talem brings in working for other companys. We are getting the Nano Consortium share and Polytope absolutely free at this share price. On top of that we get massive intellectual property and patents and full partnerships with the likes of Janssen. This was the safest and most exciting pharma play I could find because of all this. IMO our patience will soon be rewarded. GLTA
  • A
    Aprendiz
    What a non sense, promising results, this should be a 35-40$ stock.
    Bad PR by the company and lack of mature investors.
    Company must accelerate and execute partnerships to move ahead.
    Time-window is narrowing.
  • b
    beurs
    News out...big news